Heinz Hammerlindl, PhD
Assistant Researcher
Pharmaceutical Chemistry
School of Pharmacy

Publications (20)

Top publication keywords:
High-Throughput Screening AssaysProto-Oncogene Proteins B-rafLignansras ProteinsNeoplasmsDrug DiscoverySmall Molecule LibrariesAspirinOximesNeoplasm, ResidualAMP-Activated Protein KinasesHistonesIntestinal DiseasesPeptides, CyclicDrug Resistance, Neoplasm

• ResMap: A community resource for systematic mapping of therapy-persistent residual cancer cell dependencies across contexts.
  Science advances 2026 Sun X, Gayathri S, Kumbier K, Hammerlindl H, Ahern E, Wu LF, Altschuler SJ
• Programmable microparticles rewire CAR signaling to enable super-physiological expansion of human T cells in vitro.
  bioRxiv : the preprint server for biology 2025 Zeng Q, Flemming L, Chen Y, Mazumder T, Hammerlindl H, Allen GM, Almeida R, Williams JZ, Hernández-López RA, Eyquem J, Ye CJ, Lim WA, Tang Q, Desai TA, Huang X
• Transitive prediction of small-molecule function through alignment of high-content screening resources.
  Nature biotechnology 2025 Bao F, Li L, Hammerlindl H, Shen SQ, Hammerlindl S, Altschuler SJ, Wu LF
• A phenopushing platform to identify compounds that alleviate acute hypoxic stress by fast-tracking cellular adaptation.
  Nature communications 2025 Li L, Hammerlindl H, Shen SQ, Bao F, Hammerlindl S, Altschuler SJ, Wu LF
• Implantation of engineered adipocytes suppresses tumor progression in cancer models.
  Nature biotechnology 2025 Nguyen HP, An K, Ito Y, Kharbikar BN, Sheng R, Paredes B, Murray E, Pham K, Bruck M, Zhou X, Biellak C, Ushiki A, Nobuhara M, Fong SL, Bernards DA, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, …

Show all (15 more) Hide

• Cyclic tachyplesin I kills proliferative, non-proliferative and drug-resistant melanoma cells without inducing resistance.
  Pharmacological research 2024 Benfield AH, Vernen F, Young RSE, Nadal-Bufí F, Lamb H, Hammerlindl H, Craik DJ, Schaider H, Lawrence N, Blanksby SJ, Henriques ST
• Small molecule in situ resin capture provides a compound first approach to natural product discovery.
  Nature communications 2024 Bogdanov A, Salib MN, Chase AB, Hammerlindl H, Muskat MN, Luedtke S, da Silva EB, O'Donoghue AJ, Wu LF, Altschuler SJ, Molinski TF, Jensen PR
• H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase.
  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2023 Ravindran Menon D, Hammerlindl H, Gimenez G, Hammerlindl S, Zuegner E, Torrano J, Bordag N, Emran AA, Giam M, Denil S, Pavelka N, Tan AC, Sturm RA, Haass NK, Rancati G, Herlyn M, Magnes C, Eccles MR, …
• Small Molecule in situ Resin Capture - A Compound First Approach to Natural Product Discovery.
  bioRxiv : the preprint server for biology 2023 Bogdanov A, Salib MN, Chase AB, Hammerlindl H, Muskat MN, Luedtke S, Barbosa da Silva E, O'Donoghue AJ, Wu LF, Altschuler SJ, Molinski TF, Jensen PR
• Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression.
  bioRxiv : the preprint server for biology 2023 Nguyen HP, Sheng R, Murray E, Ito Y, Bruck M, Biellak C, An K, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Esserman L, Rosenbluth JM, Ahituv N
• Modulating environmental signals to reveal mechanisms and vulnerabilities of cancer persisters.
  Science advances 2022 Sun X, Bieber JM, Hammerlindl H, Chalkley RJ, Li KH, Burlingame AL, Jacobson MP, Wu LF, Altschuler SJ
• Differential toxicity to murine small and large intestinal epithelium induced by oncology drugs.
  Communications biology 2022 Bieber JM, Sanman LE, Sun X, Hammerlindl H, Bao F, Roth MA, Koleske ML, Huang L, Aweeka F, Wu LF, Altschuler SJ
• Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer.
  Theranostics 2020 Ravindran Menon D, Hammerlindl H, Torrano J, Schaider H, Fujita M
• Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer.
  Epigenomics 2019 Emran AA, Marzese DM, Menon DR, Hammerlindl H, Ahmed F, Richtig E, Duijf P, Hoon DS, Schaider H
• Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.
  Clinical epigenetics 2019 Torrano J, Al Emran A, Hammerlindl H, Schaider H
• Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma.
  Cancer medicine 2019 Emran AA, Chinna Chowdary BR, Ahmed F, Hammerlindl H, Huefner A, Haass NK, Schuehly W, Schaider H
• Distinct histone modifications denote early stress-induced drug tolerance in cancer.
  Oncotarget 2017 Emran AA, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, Flaherty K, Hoon DSB, Gabrielli B, …
• Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Hammerlindl H, Ravindran Menon D, Hammerlindl S, Emran AA, Torrano J, Sproesser K, Thakkar D, Xiao M, Atkinson VG, Gabrielli B, Haass NK, Herlyn M, Krepler C, Schaider H
• Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance.
  Journal of cell communication and signaling 2017 Hammerlindl H, Schaider H
• Notch4 Signaling Induces a Mesenchymal-Epithelial-like Transition in Melanoma Cells to Suppress Malignant Behaviors.
  Cancer research 2016 Bonyadi Rad E, Hammerlindl H, Wels C, Popper U, Ravindran Menon D, Breiteneder H, Kitzwoegerer M, Hafner C, Herlyn M, Bergler H, Schaider H